A Multinational Phase III Study of CS-8958 (MARVEL)

PHASE3CompletedINTERVENTIONAL
Enrollment

1,002

Participants

Timeline

Start Date

November 30, 2008

Primary Completion Date

March 31, 2009

Study Completion Date

June 30, 2009

Conditions
Influenza, Human
Interventions
DRUG

CS-8958

CS-8958 powder 20 mg to be inhaled one time. Oseltamivir phosphate placebo capsules 2 times per day for 5 days

DRUG

CS-8958

CS-8958 powder 40 mg to be inhaled one time. Oseltamivir phosphate placebo capsules 2 times per day for 5 days

DRUG

oseltamivir phosphate

CS-8958 placebo powder to be inhaled one time. Oseltamivir phosphate oral capsules taken twice daily for 5 days.

Trial Locations (4)

Unknown

Hong Kong

Tokyo

Seoul

Taipei

Sponsors
All Listed Sponsors
lead

Daiichi Sankyo Co., Ltd.

INDUSTRY